{"id":"W2089560299","doi":"10.3810/pgm.2010.01.2108","title":"Reaching HbA<sub>1c</sub>Goals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs","year":2010,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Saxagliptin; Medicine; Glycemic; Type 2 diabetes; Vildagliptin; Hypoglycemia; Postprandial; Tolerability; Diabetes mellitus; Glycated hemoglobin; Dipeptidyl peptidase-4 inhibitor; Internal medicine; Metformin; Pharmacology; Endocrinology; Adverse effect; Sitagliptin","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001086998,0.001040139,0.00342937,0.00111144,0.00009192374,0.00003966193,0.0002716018,0.00031174,0.00006551595],"category_scores_gemma":[0.0001242815,0.0005897976,0.0001978081,0.001050325,0.0003596554,0.0001467898,0.00008223651,0.001140315,0.0001260816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003269058,"about_ca_system_score_gemma":0.0002360877,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002791758,"about_ca_topic_score_gemma":0.0001945658,"domain_scores_codex":[0.9960603,0.0002494737,0.0009813784,0.0009249757,0.0009749215,0.0008089802],"domain_scores_gemma":[0.9976757,0.0002374815,0.0006818692,0.0009206847,0.0001642002,0.0003200748],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001379599,0.0006624975,0.001600742,0.009472141,0.0007128019,0.0002933681,0.000480815,2.662606e-7,0.00005400419,0.0002329261,0.0008123773,0.9855401],"study_design_scores_gemma":[0.01123567,0.004027471,0.001060999,0.08318111,0.008733856,0.0001239505,0.0001511829,0.00002065341,0.0001306144,0.00008577506,0.8902695,0.0009792402],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02789144,0.9554837,0.00004684714,0.002875677,0.0004159601,0.005342554,0.00002078055,0.0002595566,0.00766353],"genre_scores_gemma":[0.009847187,0.9848782,0.0006658687,0.0007229424,0.0003646644,0.0004329837,0.001169166,0.0003236508,0.001595348],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9845608,"threshold_uncertainty_score":0.9996554,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03119454403990676,"score_gpt":0.3018268130513877,"score_spread":0.270632269011481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}